Clera home
·Dashboard

Jobs at HAYA Therapeutics (Now Hiring) — 2 open

HAYA Therapeutics logoHAYA Therapeutics

Director, CMC (Therapeutic Oligonucleotides)

San Diego, California, United States · On-site

Senior+$1.1B raised

Lead the global chemistry, manufacturing, and controls (CMC) strategy, process optimization, and contract manufacturing network for therapeutic oligonucleotides to ensure the seamless, compliant supply of drug substance …

Skills: CMC Strategy, Oligonucleotide Chemistry, CDMO Management, cGMP Manufacturing, Technology Transfer

HAYA Therapeutics logoHAYA Therapeutics

Director, CMC (Therapeutic Oligonucleotides)

San Diego, California, United States · On-site

Senior+$1.1B raised

Lead the global chemistry, manufacturing, and controls (CMC) strategy, process optimization, and contract manufacturing network for therapeutic oligonucleotides to ensure the seamless, compliant supply of drug substance …

Skills: CMC Strategy, Oligonucleotide Synthesis, CDMO Management, cGMP Compliance, Analytical Method Validation

HAYA Therapeutics logo

Director, CMC (Therapeutic Oligonucleotides)

HAYA Therapeutics

San Diego, California, United States • On-site

Apply
Senior+

Tired of cold applications?

Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.

  • Full-time
  • postgraduate degree
  • Posted 17d ago
  • ~40 hrs/week

Responsibilities

Lead the global CMC strategy and manage the contract manufacturing network for therapeutic oligonucleotides from discovery through clinical testing. Oversee process optimization, analytical validation, and the authoring of technical regulatory filings to ensure compliant drug supply.

Requirements

Requires a PhD in Organic Chemistry, Biochemistry, or a related field with deep technical expertise in oligonucleotide chemistry and cGMP manufacturing. Must have proven experience managing international CDMOs and a thorough understanding of FDA and EMA regulatory guidelines.

Full job description

Lead the global chemistry, manufacturing, and controls (CMC) strategy, process optimization, and contract manufacturing network for therapeutic oligonucleotides to ensure the seamless, compliant supply of drug substance and drug product across clinical pipeline phases.

Accountabilities:

  • Design and execute phase-appropriate global CMC development strategies for therapeutic oligonucleotides from late-stage discovery through advanced clinical testing to achieve corporate pipeline milestones.
  • Direct external Contract Development and Manufacturing Organizations (CDMOs) and analytical testing laboratories, overseeing technology transfers, process scale-ups, and cGMP campaigns.
  • Optimize solid-phase oligonucleotide synthesis, cleavage, deprotection, purification, and lyophilization processes to maximize production yields and ensure operational efficiency.
  • Oversee the development, qualification, and validation of analytical methods for release testing, stability monitoring, and impurity characterization to maintain high product quality.
  • Partner with the Quality Assurance team to review and approve master batch records, executed runs, and stability protocols to ensure unconditional compliance with cGMP and phase-appropriate regulatory guidelines.
  • Author, review, and finalize CMC technical sections (Module 3) for global regulatory filings (including INDs, IMPDs, and NDAs) to facilitate rapid health authority approvals.
  • Formulate technical data packages and precise written responses to CMC-related inquiries from global regulatory agencies (including the US FDA and EMA).
  • Serve as the primary CMC representative on cross-functional program teams, collaborating closely with Discovery Biology, Translational Research, Regulatory Affairs, and Clinical Operations to ensure clinical trial material readiness.
  • Forecast long-term chemical material needs and manage chemical raw inventory pools (including amidites and solid supports) to de-risk global clinical supply chains.

Required Knowledge and Experience

  • Demonstrated technical depth leading outsourced cGMP manufacturing operations and managing technology transfers with international CDMOs.
  • Proven competence in therapeutic oligonucleotide chemistry (including ASOs, siRNA, and sgRNA), phosphoramidite workflows, conjugation strategies, and advanced purification techniques.
  • Advanced working knowledge of analytical chemistry specific to oligonucleotides, with deep expertise in sequence confirmation, impurity profiling, and stability control strategies.
  • Thorough understanding of global regulatory guidelines (ICH, FDA, and EMA) regarding the development, characterization, and manufacturing specifications of synthetic oligonucleotides.
  • Exposure to or direct experience tracking targeted delivery systems for oligonucleotides, such as GalNAc conjugates or lipid nanoparticles (LNPs).
  • Advanced educational background (PhD level preferred) in Organic Chemistry, Biochemistry, Chemical Engineering, or a highly related life sciences discipline.

HAYA Therapeutics is an Equal Opportunity Employer committed to fostering a diverse, inclusive, and equitable workplace where all individuals feel valued and empowered. We provide equal employment opportunities to all qualified applicants and employees without regard to race, color, religion, sex (including pregnancy, sexual orientation, gender identity, or gender expression), national origin, ancestry, age, marital or familial status, veteran status, disability, genetic information, or any other characteristic protected by applicable federal, state, or local laws.

We prohibit discrimination and harassment of any kind and are committed to ensuring fair and equitable treatment in all aspects of recruitment, hiring, promotion, compensation, benefits, training, and career development.

At HAYA, we believe that diversity of thought, experience, and background drives innovation and strengthens our mission to transform patient care through cutting-edge RNA-based therapeutics.

Related keywords

CMCTherapeutic OligonucleotidesASOssiRNAsgRNAPhosphoramiditecGMPCDMOINDIMPDNDAFDAEMAICHGalNAcLipid Nanoparticles

About HAYA Therapeutics

LinkedInVisit site

Programmable Therapeutics for Causal Biology - Science Guides Us. The Genome Powers Us. Patients Ground Us.

Industry
Biotechnology Research
Company size
11-50 employees
Founded
2019
Headquarters
Lausanne - Switzerland / San Diego - USA
LinkedIn followers
22,329
Total funding
$1.1B

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Offices: Route De La Corniche 5B, SuperLab Suisse - Batiment Alanine, Lausanne - Switzerland / San Diego - USA, CH · 10935 Alexandria Way, 101 & 102, San Diego, California 92121, US

lncRNAgenomic medicinesfibrosisCausal BiologyProgrammable TherapeuticsRegulatory Genomeand Reprogramming Cell StatesHealth CareBiopharmaBiotechnology
View all jobs at HAYA Therapeutics

About HAYA Therapeutics

LinkedInVisit site

Programmable Therapeutics for Causal Biology - Science Guides Us. The Genome Powers Us. Patients Ground Us.

Industry
Biotechnology Research
Company size
11-50 employees
Founded
2019
Headquarters
Lausanne - Switzerland / San Diego - USA
LinkedIn followers
22,329
Total funding
$1.1B

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Offices: Route De La Corniche 5B, SuperLab Suisse - Batiment Alanine, Lausanne - Switzerland / San Diego - USA, CH · 10935 Alexandria Way, 101 & 102, San Diego, California 92121, US

lncRNAgenomic medicinesfibrosisCausal BiologyProgrammable TherapeuticsRegulatory Genomeand Reprogramming Cell StatesHealth CareBiopharmaBiotechnology
View all jobs at HAYA Therapeutics

Similar companies hiring

Thermo Fisher Scientific (2404)Roche (1195)CSL (1011)Amgen (880)ICON plc (783)Syneos Health (410)Mineralys Therapeutics, Inc. (312)Fortrea (267)Agilent Technologies (262)Gilead Sciences (218)BeiGene (187)Genentech (179)
Clera home

Your AI-talent agent. Connecting talents with dream jobs.

Earn $5,000

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Case Studies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Case Studies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

© 2026 Clera Labs, Inc.

PrivacyTermsBug Bounty